Contineum Therapeutics (CTNM) reported late Monday dosing of the first cohort of patients in the PIPE-791 phase 1b positron emission tomography trial.
The study is expected to measure the correlation of pharmacokinetics to receptor occupancy by positron emission tomography imaging in healthy volunteers, as well as idiopathic pulmonary fibrosis and progressive multiple sclerosis patients, it said.
Contineum said it expects topline data from the trial in Q2 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。